Fresenius - the health care group
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS) and Joslin Diabetes Center, Inc., the world's preeminent diabetes research, clinical care and education organization, announced an agreement today to jointly develop renal care programs in select Joslin Affiliated Centers for patients with diabetic kidney disease (DKD).>>>
Fresenius Medical Care hosted a Capital Markets Day on April 3 in New York. The event was aimed at giving analysts and investors further insight into Fresenius Medical Care’s vision for 2020 and the growth and efficiency strategies the company is pursuing>>>
Fresenius has fixed the initial conversion price of the equity-neutral convertible bonds placed on March 18, 2014.>>>
Fresenius successfully placed €500 million equity-neutral convertible bonds due 2019.>>>
Fresenius intends to issue €375 million equity-neutral convertible bonds due 2019.>>>